Preliminary Evaluation of Uptake of [68Ga]P16-093 in Metastatic Prostate and Renal Cancer

NCT03073395 | Completed Phase 1 FDA Drug

• 1 other identifier: 511-0003-A
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

An phase I study to evaluate the uptake of \[68Ga\]P16-093 in known or suspected metastatic prostate or renal cancer to establish the feasibility of using \[68Ga\]P16-093 to image PSMA expressing cancer. Measurement of the whole body biodistribution of \[68Ga\]P16-093 in prostate cancer patients post primary curative-intent treatment with stable PSA to generate human radiation dosimetry data.

Conditions

Prostate Cancer; Renal Cancer

Outcome Measures

Primary Outcomes (2)

• Uptake of [68Ga]P16-093 in metastatic prostate and renal cancer

  Standard uptake value (SUV) of \[68Ga\]P16-093 in apparent lesions detected by PET/CT.

  0.5 - 3 hours after injection

• Radiation dosimetry of [68Ga]P16-093 in patients with a history of prostate cancer

  Radiation dosimetry (organ absorbed dose and effective dose) will be determined using region of interest data drawn on sequential PET/CT images and data from blood and / or urine obtained during scanning.

  up to 3 hours after injection

Study Arms (2)

Dynamic group

EXPERIMENTAL

Dynamic imaging of suspected metastatic lesions with the investigation drug \[68Ga\]P16-093 in patients with a history of histologically confirmed cancer.

Drug: [68Ga]P16-093

Biodistribution group

EXPERIMENTAL

Whole body imaging to determine human dosimetry of the investigational drug \[68Ga\]P16-093

Drug: [68Ga]P16-093

Interventions

[68Ga]P16-093 DRUG

Imaging by Positron Emission Tomography after iv injection of \[68Ga\]P16-093

Biodistribution group; Dynamic group

Eligibility Criteria

• Age: 18 Years+
• Sex: male
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Participants will be male ≥ 18 years of age
• History of histologically confirmed cancer that meets criteria for either a) or b)
• Prostate cancer with known or suspected recurrent or metastatic disease based on clinical imaging (e.g. CT, bone scan, MRI, ultrasound, FDG PET/CT, FACBC PET/CT) within 12 months of screening. If subject is post curative-intent local treatment (e.g. radical prostatectomy, local radiotherapy, brachytherapy) they must have had no intervening change in cancer treatment.
• Renal Cell cancer with known or suspected metastatic disease based on clinical imaging (e.g. CT, bone scan, MRI, ultrasound, FDG PET/CT)
• Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures.

You may not qualify if:

• Estimated creatinine clearance (eGFR) \< 30 mL/min (calculated from serum creatinine result within 30 days of screening)
• Chemotherapy or radiation therapy within 2 weeks of screening
• Inability to tolerate imaging procedures in the opinion of an investigator or treating physician
• Any current medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful completion of the study
• BIODISTRIBUTION GROUP:
• Participants will be male ≥ 18 years of age
• History of prostate cancer that is post curative-intent local treatment (e.g. radical prostatectomy, local radiotherapy, brachytherapy) with clinical PSA levels that meet one of the following criteria
• Post-Prostatectomy (with or without adjuvant RT): PSA level that is \< 0.2 ng/mL measured over at least 2 consecutive tests OR
• Post-Radiotherapy: PSA level that has not risen from nadir measured over at least 2 consecutive tests
• If clinical imaging (e.g. bone scan, CT, MRI, ultrasound, PET/CT) has been done within 3 months of screening as part of standard clinical surveillance it must be negative or equivocal for sites of recurrent or metastatic disease (clinical imaging is not required for enrollment)
• Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures.
• Estimated creatinine clearance (eGFR) \< 30 mL/min (calculated from serum creatinine result within 30 days of screening)
• Androgen deprivation therapy (ADT) within 3 months prior to screening
• Chemotherapy or radiation therapy within 2 weeks of screening
• Inability to tolerate imaging procedures in the opinion of an investigator or treating physician

Sponsors & Collaborators

• Five Eleven Pharma, Inc.: lead

Study Sites (1)

University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

Location

MeSH Terms

Conditions

Prostatic Neoplasms; Kidney Neoplasms

Condition Hierarchy (Ancestors)

Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Prostatic Diseases; Male Urogenital Diseases; Urologic Neoplasms; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Kidney Diseases; Urologic Diseases

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: DIAGNOSTIC
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 28, 2017
• First Posted: March 8, 2017
• Study Start: July 21, 2017
• Primary Completion: October 27, 2023
• Study Completion: October 27, 2023
• Last Updated: February 26, 2025

Record last verified: 2025-02

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)